In this handout photo released by Russian Direct Investment Fund, a view shows a phial of Russian Sputnik-Light one-dose vaccine against the coronavirus disease (COVID-19) developed by the Gamaleya Scientific Research Institute of Epidemiology and Microbiology during clinical trials, in Moscow, Russia. Sputnik-Light is based on the same special structures (carrier vectors) as in two-dose Russian Gam-COVID-VAK (trademark "Sputnik V") vaccine. Russia has described Sputnik-Light, which could be used for export, as a possible temporary solution to help countries with high infection rates make their vaccine supplies go further. Editorial use only, no archive, no commercial use.
|Categories:||Science & Technology, Health, Social Issues|
|Feature:||Russia Coronavirus Vaccine|
|Keywords:||SARS-CoV-2, COVID, COVID-19, virus, pandemic, epidemic, infection, 2019-nCoV, coronavirus, disease|
|Source:||Russian Direct Investment Fund (RDIF)|